Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/10/12
End: 02/27/14
Due: 02/27/15
Phase: N/A
Priority: Normal
Start: 01/22/20
End: 11/01/31
Due: 11/01/32
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma | NCT04274816 | A.J.M. van den Eertwegh | user2@example.com | None | 2012-07-10 | 2014-02-27 | 2015-02-27 | - | - | 2025-07-14 |
| A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma | NCT04126876 | A.J.M. van den Eertwegh | user2@example.com | None | 2020-01-22 | 2031-11-01 | 2032-11-01 | - | - | 2025-07-14 |